Johanna Bruce

Johanna Bruce

Auto-generated profile, based on publicly available information

Johanna Bruce

Université Paris Cité, P53 proteom’IC facility, Institut Cochin, INSERM, CNRS, Paris, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
EMEmilie Murigneux
Emilie Murigneux
LSLaurent Softic
Laurent Softic
CACorentin Aubé
Corentin Aubé
CGCarmen Grandi
Carmen Grandi
DJDelphine Judith
Delphine Judith
SGSarah Gallois-Montbrun
Sarah Gallois-Montbrun
Considerable progress has been made in understanding the molecular host-virus battlefield during SARS-CoV-2 infection. Nevertheless, the assembly and egress of newly formed virions are less understood. To identify host proteins involved in viral morphogenesis, we characterize the proteome of SARS-CoV-2 virions produced from A549-ACE2 and Calu-3 cells, isolated via ultracentrifugation on sucrose cushion or by ACE-2 affinity capture. Bioinformatic analysis unveils 92 SARS-CoV-2 virion-associated host factors, providing a valuable resource to better understand the molecular environment of virion production. We reveal that G3BP1 and G3BP2 (G3BP1/2), two major stress granule nucleators, are embedded within virions and unexpectedly favor virion production. Furthermore, we show that G3BP1/2 participate in the formation of cytoplasmic membrane vesicles, that are likely virion assembly sites, consistent with a proviral role of G3BP1/2 in SARS-CoV-2 dissemination. Altogether, these findings provide new insights into host factors required for SARS-CoV-2 assembly with potential implications for future therapeutic targeting.

28 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
TYThulaciga Yoganathan
Thulaciga Yoganathan
MPMailyn Pérez-Liva
Mailyn Pérez-Liva
DBDaniel Balvay
Daniel Balvay
MGMorgane Le Gall
Morgane Le Gall
ALAlice Lallemand
Alice Lallemand
BTBertrand Tavitian
Bertrand Tavitian
Takotsubo cardiomyopathy is a stress-induced cardiovascular disease with symptoms comparable to those of an acute coronary syndrome but without coronary obstruction. Takotsubo was initially considered spontaneously reversible, but epidemiological studies revealed significant long-term morbidity and mortality, the reason for which is unknown. Here, we show in a female rodent model that a single pharmacological challenge creates a stress-induced cardiomyopathy similar to Takotsubo. The acute response involves changes in blood and tissue biomarkers and in cardiac in vivo imaging acquired with ultrasound, magnetic resonance and positron emission tomography. Longitudinal follow up using in vivo imaging, histochemistry, protein and proteomics analyses evidences a continued metabolic reprogramming of the heart towards metabolic malfunction, eventually leading to irreversible damage in cardiac function and structure. The results combat the supposed reversibility of Takotsubo, point to dysregulation of glucose metabolic pathways as a main cause of long-term cardiac disease and support early therapeutic management of Takotsubo.

1 July 2021 in Differentiation
Verified
Journal Article
Closed access
MDMathieu Danoy
Mathieu Danoy
RJRachid Jellali
Rachid Jellali
YTYannick Tauran
Yannick Tauran
JBJohanna Bruce
Johanna Bruce
MLMarjorie Leduc
Marjorie Leduc
ELEric Leclerc
Eric Leclerc

12 July 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
TYThulaciga Yoganathan
Thulaciga Yoganathan
MPMailyn Pérez-Liva
Mailyn Pérez-Liva
DBDaniel Balvay
Daniel Balvay
MGMorgane Le Gall
Morgane Le Gall
ALAlice Lallemand
Alice Lallemand
BTBertrand Tavitian
Bertrand Tavitian

12 September 2025 in bioRxiv
Verified
Preprint
Open access
VGVirgile Gibert
Virgile Gibert
FMFrédérique Maczkowiak-Chartois
Frédérique Maczkowiak-Chartois
BMBenedetta Mancini
Benedetta Mancini
EGEmilie-Fleur GAUTIER
Emilie-Fleur GAUTIER
JBJohanna Bruce
Johanna Bruce
FRFilippo Rosselli
Filippo Rosselli
Fanconi Anemia (FA) is a rare inherited recessive disorder characterized by bone marrow failure, congenital abnormalities, and a predisposition to myeloid leukemia and some solid cancers. FA is caused by mutations in one of the 22 so-called FANC genes, with two thirds of FA patients being FANCA mutants. FANC proteins cooperate within the FANC/BRCA pathway, a DNA repair system essential for resolving DNA interstrand crosslinks (ICLs) in S-phase. The canonical understanding of FA pathogenesis involves genome instability and impaired cellular proliferation due to DNA damage accumulation and stress response overactivation. However, recent data shows FANCA has a function in ribosome biogenesis and translation, which prompts a reassessment of FANCA’s role(s) in cellular physiology and FA pathogenesis. We reasoned that unveiling the multiple interactions of the FANCA protein would shed light on these potentially new FANCA functions. By combining immunoprecipitation and BioID approaches, in three different cell lines and with different in silico analysis methods, we constructed lists of FANCA interactome proteins of different levels of selectivity and assembled them into a novel multilayered FANCA protein-protein interaction (PPI) landscape. Strikingly, we find that FANCA associates with proteins involved in processes distinct from DNA repair, such as translation, ribosome biogenesis, mRNA splicing, nucleocytoplasmic transport, chromatin remodeling, and the TCA cycle. We then analyzed the protein content of polysome profiling fractions and found that FANCA loss may affect ribosomal protein stoichiometry within ribosomal subunits. Overall, our data expands FANCA’s PPI network far beyond the previously reported interactions. Importantly, we confirm the biological significance of low-selectivity interactions and propose to re-evaluate their importance in proteomic studies. The study of previously unsuspected FANCA functions, such as translation, could provide new therapeutic targets in FA and therefore improve patient care.